Loss of GLUT4 induces metabolic reprogramming and impairs viability of breast cancer cells

Journal of Cellular Physiology

Volumn 230, Issue 1, 2015, Pages 191-198

  Garrido, Pablo ^a   Osorio, Fernando G ^a   Morán, Javier ^a   Cabello, Estefanía ^a   Alonso, Ana ^a   Freije, José M P ^a   González, Celestino ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEOXYGLUCOSE; GLUCOSE TRANSPORTER 4; LACTIC ACID; PROTEIN BCL 2; PROTEIN KINASE B; PYRUVIC ACID; SHORT HAIRPIN RNA; TRITIUM; GLUCOSE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; SLC2A4 PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; ENZYME ACTIVATION; GENE SILENCING; GLUCOSE TRANSPORT; MCF 7 CELL LINE; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; MTT ASSAY; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; WESTERN BLOTTING; APOPTOSIS; BREAST TUMOR; CELL HYPOXIA; CELL SURVIVAL; CHEMISTRY; DOWN REGULATION; ENERGY METABOLISM; FEMALE; GENETICS; GLYCOLYSIS; HUMAN; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

APOPTOSIS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; ENERGY METABOLISM; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLYCOLYSIS; HUMANS; LACTIC ACID; MCF-7 CELLS; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVIC ACID; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES;

EID: 84910028645     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24698     Document Type: Article

References (46)

1. Aft RL, Zhang FW, Gius D. 2002. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell death. Br J Cancer 87:805-812.
2. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. 2009. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909-915.
3. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. 2004. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775.
4. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB. 2005. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24:4165-4173.
5. Caro-Maldonado A, Munoz-Pinedo C. 2011. Dying for something to eat: How cells respond to starvation. Open Cell Signal J 3:42-51.
6. Cascio S, Bartella V, Auriemma A, Johannes GJ, Russo A, Giordano A, Surmacz E. 2008. Mechanism of leptin expression in breast cancer cells: Role of hypoxia-inducible factor-1alpha. Oncogene 27:540-547.
7. Charron MJ, Brosius FC, III, Alper SL, Lodish HF. 1989. A glucose transport protein expressed predominately in insulin-responsive tissues. Proc Natl Acad Sci USA 86:2535-2539.
8. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, Cantley LC, Blenis J. 2010. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 38:487-499.
9. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11-20.
10. Edinger AL, Thompson CB. 2002. Akt maintains cell size and survival by increasing mTORdependent nutrient uptake. Mol Biol Cell 13:2276-2288.
11. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. 2004. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892-3899.
12. Garrido P, Moran J, Alonso A, Gonzalez S, Gonzalez C. 2013. 17beta-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology 154:1979-1989.
13. Gatenby RA, Gillies RJ. 2004. Why do cancers have high aerobic glycolysis. Nat Rev Cancer 4:891-899.
14. Grillo CA, Piroli GG, Hendry RM, Reagan LP. 2009. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 1296:35-45.
15. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646-674.
16. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A. 2006. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66:4368-4377.
17. Hervouet E, Pecina P, Demont J, Vojtiskova A, Simonnet H, Houstek J, Godinot C. 2006. Inhibition of cytochrome c oxidase subunit 4 precursor processing by the hypoxia mimic cobalt chloride. Biochem Biophys Res Commun 344:1086-1093.
18. Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S, Barnard N, Ganesan S, Karantza V, White E, Xia B. 2013. Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer. Cancer Discov 3:894-907.
19. Jin S, DiPaola RS, Mathew R, White E. 2007. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 120:379-383.
20. Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, Lu J. 2012. Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol 32:1893-1907.
21. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP. 2011. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108:3749-3754.
22. Knobbe CB, Merlo A, Reifenberger G. 2002. Pten signaling in gliomas. Neuro Oncol 4:196-211.
23. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. 1996. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271:31372-31378.
24. Luo J, Solimini NL, Elledge SJ. 2009. Principles of cancer therapy: Oncogene and nononcogene addiction. Cell 136:823-837.
25. Marino G, Ugalde AP, Salvador-Montoliu N, Varela I,Quiros PM, Cadinanos J, van der Pluijm I, Freije JM, Lopez-Otin C. 2008. Premature aging in mice activates a systemic metabolic response involving autophagy induction. Hum Mol Genet 17:2196-2211.
26. MedinaRA,MenesesAM,Vera JC,GuzmanC,NualartF,AstuyaA,GarciaMA,KatoS,CarvajalA, Pinto M, Owen GI. 2003. Estrogen and progesterone up-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. Endocrinology 144:4527-4535.
27. Menendez JA, Oliveras-Ferraros C, Cufi S, Corominas-Faja B, Joven J, Martin-Castillo B, Vazquez-Martin A. 2012. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 11:2782-2792.
28. Moreira L, Araujo I, Costa T, Correia-Branco A, Faria A, Martel F, Keating E. 2013. Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp Cell Res 319:1784-1795.
29. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, Kroemer G. 2010. The life spanprolonging effect of sirtuin-1 is mediated by autophagy. Autophagy 6:186-188.
30. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV. 2005. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114:242-248.
31. Piret JP, Mottet D, Raes M, Michiels C. 2002. CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann NY Acad Sci 973:443-447.
32. Plas DR, Thompson CB. 2005. Akt-dependent transformation: There is more to growth than just surviving. Oncogene 24:7435-7442.
33. Roccisana J, Sadler JB, Bryant NJ, Gould GW. 2013. Sorting of GLUT4 into its insulinsensitive store requires the Sec1/Munc18 protein mVps45. Mol Biol Cell 24:2389-2397.
34. Saunders LR, Verdin E. 2007. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 26:5489-5504.
35. Sutherland R, Freyer J, Mueller-Klieser W, Wilson R, Heacock C, Sciandra J, Sordat B. 1986. Cellular growth and metabolic adaptations to nutrient stress environments in tumor microregions. Int J Radiat Oncol Biol Phys 12:611-615.
36. Swerdlow RH, Lezi E, Aires D, Lu J. 2013. Glycolysis-respiration relationships in a neuroblastoma cell line. Biochim Biophys Acta 1830:2891-2898.
37. Vahsen N, Cande C, Briere JJ, Benit P, Joza N, Larochette N, Mastroberardino PG, Pequignot MO, Casares N, Lazar V, FeraudO, Debili N,Wissing S, Engelhardt S, Madeo F, Piacentini M, Penninger JM, Schagger H, Rustin P, KroemerG. 2004. AIF deficiency compromises oxidative phosphorylation. EMBO J 23:4679-4689.
38. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
39. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. 2001. Growth factors can influence cell growth and survival through effects on glucose metabolism. MolCell Biol 21:5899-5912.
40. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, Klip A. 1999. Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol 19:4008-4018.
41. Warburg O. 1956. On the origin of cancer cells. Science 123:309-314.
42. Warburg O, Wind F, Negelein E. 1927. The metabolism of tumors in the body. J Gen Physiol 8:519-530.
43. Ward PS, Thompson CB. 2012. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 21:297-308.
44. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, Somlo G, Yen Y. 2011. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 30:4437-4446.
45. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. 1995. GLUT1 expression in human breast carcinoma: Correlation with known prognostic markers. Anticancer Res 15 2895-2898.
46. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. 1996. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 56:1164-1167.